Status:
COMPLETED
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Astellas Pharma Inc
Conditions:
Prostatic Neoplasms, Castration-Resistant
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC). Pros...
Eligibility Criteria
Inclusion
- Male with metastatic prostate cancer diagnosis and abstracted castration-resistant prostate cancer diagnosis
- Initiated enzalutamide or abiraterone within 14 days prior to or after the metastatic castration-resistant prostate cancer diagnosis. The initiation date of enzalutamide or abiraterone will be defined as the index date.
- At least 18 years old at the index date
Exclusion
- Received chemotherapy, novel hormonal therapy, radium-223, olaparib/rucaparib, or immunotherapy prior to the index date
- Had a prior history of other cancers
Key Trial Info
Start Date :
July 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 14 2025
Estimated Enrollment :
2731 Patients enrolled
Trial Details
Trial ID
NCT05968599
Start Date
July 24 2023
End Date
February 14 2025
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Inc
New York, New York, United States, 10001